Clinical Trials Logo

Liver Diseases clinical trials

View clinical trials related to Liver Diseases.

Filter by:

NCT ID: NCT03416387 Recruiting - Surgery Clinical Trials

Applicability of 3D Printing and 3D Digital Image Reconstruction in the Planning of Complex Liver Surgery (LIV3DPRINT).

LIV3DPRINT
Start date: June 23, 2017
Phase: N/A
Study type: Interventional

Three-dimensional (3D) printing has gained popularity in medicine over the last decade. Once 3D printers have become more affordable, the true strength of this technique has been recognized because of its ability to obtain anatomical models based on the unique characteristics of each patient. Liver resections are challenging operations because of the complex nature of the liver and venous anatomy within the liver, so 3D imaging is a promising new tool for surgical planning.

NCT ID: NCT03388320 Recruiting - Clinical trials for Liver Diseases, Alcoholic

Using Addiction Comprehensive Health Enhancement Support System (ACHESS) in an Alcoholic Liver Disease Population

Start date: April 24, 2018
Phase: N/A
Study type: Interventional

This is a pilot study examining whether an evidence-based recovery support smartphone application, the Addiction Comprehensive Health Enhancement Support System (A-CHESS), can decrease alcohol recidivism in a previously unstudied group of patients with alcoholic liver disease (ALD).

NCT ID: NCT03308916 Recruiting - Fibrosis Clinical Trials

Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers

SIPHON
Start date: October 6, 2017
Phase: N/A
Study type: Interventional

Prospective screening study at Odense University Hospital to assess the effect of transient elastography and other serum and imaging markers of liver fibrosis to detect advanced fibrosis (Kleiner Fibrosis score F3-F4) in patients at risk of non-alcoholic fatty liver disease, alcoholic fatty liver disease, with a control group of participants recruited from the general population.

NCT ID: NCT03274388 Recruiting - Liver Diseases Clinical Trials

Whole Body Electromyostimulation and Nutritional Therapy for Patients With Chronic Liver Disease

Start date: January 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to explore the influence of an innovative combined therapy involving optimized protein-rich nutritional therapy and highly effective muscle training by personalized whole-body electromyostimulation (WB-EMS) exercise to improve muscle mass, strength and functionality, physical capacity, fatigue and quality of life of patients with chronic liver disease.

NCT ID: NCT03172650 Recruiting - Liver Diseases Clinical Trials

Effect of Non-alcoholic Fatty Liver Disease on Kidney Functions

Start date: July 1, 2017
Phase: N/A
Study type: Observational

Non-alcoholic fatty liver disease is the most common cause of chronic liver disease worldwide. It is defined as the accumulation of fat (>5%) in the liver cells in the absence of excessive alcohol intake or other causes of liver disease including viral, drug-induced, or autoimmune. Non-alcoholic fatty liver disease is a hepatic manifestation of metabolic syndrome.

NCT ID: NCT03074708 Recruiting - Liver Diseases Clinical Trials

Application of 3D Visualization and 3D Printing in the Hepatobiliary and Pancreatic Surgery

Start date: March 2017
Phase: N/A
Study type: Interventional

Background:The aim of the study is to value the application of three-dimensional visualization and three-dimensional printing in the hepatobiliary and pancreatic surgery.Method:From January 2016 to December 2018,the clinical data of 200 patients with the hepatobiliary and pancreatic diseases will be collected.All the patients received abdominal CT scanning and 3D reconstruction. Then we used the 3D reconstruction model and the 3D printed model based on the 3D reconstruction model in the operation planning and the operation.The clinical data include operative time, intraoperative blood loss,and postoperative complications after surgery.

NCT ID: NCT03063866 Recruiting - Liver Diseases Clinical Trials

Randomised Controlled Study of Popofol Versus Midazolam as Sedation in Endoscopy With Advanced Liver Disease.

Start date: February 21, 2017
Phase: Phase 4
Study type: Interventional

Gastrointestinal endoscopy is a frequent procedure in the patients with advanced liver disease. It requires variable degree of sedation ranging from minimal sedation to general anesthesia aiming for relieving pain, anxiety, and bad memories of the procedure. In conscious sedation, patients are able to make purposeful responses to auditory and tactile clues, with maintenance of ventilatory and circulatory stability. while, in deep sedation, patients respond only to painful stimuli, and airway support is frequently required. At the level of general anesthesia, patients are unresponsive, and airway support is mandatory.

NCT ID: NCT02943707 Recruiting - Liver Diseases Clinical Trials

Autologous Bone Marrow Stem Cells Infusion for the Treatment of Liver Diseases.

ABMSCIFTLD
Start date: October 2016
Phase: Phase 2
Study type: Interventional

This study evaluates the effect of autologous bone marrow stem cells infusion (ABMSCi) therapy for liver diseases.Treatment group will receive ABMSCi and drugs therapy ,while control group will only receive drugs therapy.

NCT ID: NCT02938871 Recruiting - Liver Disease Clinical Trials

Effect of Synbiotic on Postoperative Complications After Liver Transplantation

Start date: March 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the use of synbiotic in patients after liver transplantation and assess the effect of these agents on postoperative infections, antibiotic use, length of hospital stay, mortality and nutritional status.

NCT ID: NCT02917382 Recruiting - Liver Disease Clinical Trials

Evolution and Clinical Outcomes in Patients Undergoing Liver Transplantation

Start date: July 2013
Phase: N/A
Study type: Observational

Liver transplantation (LTx) is the standard treatment used in the final stage of chronic or acute liver failure. The success for the LT depends on many factors. One of the factors related to morbidity and mortality of these patients is malnutrition. Patients on the waiting list for LTx are increased risk of malnutrition and metabolic disorders that may be associated with decreased functional capacity, change in resting energy expenditure cardiac autonomic dysfunction. These conditions may influence the results both before and after transplantation, as the clinical outcome and complications present in the postoperative period. Therefore, this study aims to characterize and relate nutritional status, metabolic, functional and clinical outcomes in the recent postoperative patients undergoing liver transplantation. It is an observational, prospective study based on four evaluations: the first will be conducted while the patient is awaiting transplantation; and after insertion of the graft, patients will be evaluated between the 1nd and 3th postoperative day, between 5 and 7 days and at discharge from hospital. In the late post-transplant, there is the action of immunosuppressive drugs, largely responsible for increased survival, but also on the other hand, are responsible for important nutritional and metabolic disorders. Metabolic complications such as hyperkalemia, hypertension, diabetes mellitus and overweight have been described. Thus, due to the high incidence of these complications, alternative options, such as lowering the dose of immunosuppressive drugs, have been fully explored, particularly as regards association with the viability of the graft. However, few studies have evaluated whether there is change in the incidence of metabolic disorders, cited above, in relation to the different doses of immunosuppressive drugs. Furthermore these metabolic complications will be evaluated in the late post-transplant period.